脊柱肌肉缩的疾病修饰疗法的最新进展
Li-Kai Tsai1, Chen-Hung Ting2, Yo-Tsen Liu3
1Department of Neurology, National Taiwan University Hospital and National Taiwan University College of Medicine, Taipei, Taiwan.
Acta neurologica Taiwanica
|October 4, 2024
概括
脊髓肌肉缩 (SMA) 是一种运动神经元疾病,可以通过三种疾病修饰疗法治疗:nusinersen,onasemnogene abeparvovec和risdiplam. 使用这些基因疗法的早期治疗可以稳定SMA的进展并改善神经功能.
科学领域:
- 神经学 神经学
- 遗传学 是一个遗传学.
- 药理学 药理学是指药理学的学科.
背景情况:
- 脊髓肌肉缩 (SMA) 是一种自身逆性运动神经元疾病.
- SMA是由同卵性生存运动神经元1 (SMN1) 基因突变引起的.
- SMN2基因拷贝提供了增强SMN表达的目标.
研究的目的:
- 审查目前对SMA的疾病修饰疗法.
- 为了突出 nusinersen,onasemnogene abeparvovec 和 risdiplam 的有效性和使用情况.
- 强调早期干预在SMA治疗中的重要性.
主要方法:
- 对SMA疾病修饰疗法的当前文献的综述.
- 分析药物机制,施用途径和患者群体.
- 综合关于治疗有效性和结果的数据.
主要成果:
- 努辛森 (反感性寡核酸) 向SMN2前mRNA进行替代拼接,通过内注射.
- 奥纳森基因abeparvovec (腺相关病毒载体) 通过静脉注射 (一次性) 输送SMN1基因.
- 里斯迪普拉姆 (小分子) 向SMN2前mRNA,每天口服.
结论:
- 这三种疗法在治疗SMA方面表现出显著的有效性.
- 早期启动疾病修饰疗法对于稳定SMA和潜在的神经恢复至关重要.
- 在SMA治疗方面的进步为其他神经退行性疾病的药物发现提供了洞察力.
更多相关视频
05:55Delivery of Therapeutic Agents Through Intracerebroventricular ICV and Intravenous IV Injection in Mice
Published on: October 3, 2011
60.6K
06:51Systemic Delivery of MicroRNA Using Recombinant Adeno-associated Virus Serotype 9 to Treat Neuromuscular Diseases in Rodents
Published on: August 10, 2018
7.6K
相关概念视频
01:21Satellite Stem Cells and Muscular Dystrophy
1.9K
Satellite stem cells or myosatellite cells are quiescent stem cells that Alexander Mauro first identified in 1961. These cells are located between the sarcolemma, the plasma membrane of muscle fibers, and the basal lamina, the connective tissue sheath covering it. These mononucleated cells are activated in response to muscle injury, can transform into myoblasts, and may form or repair muscle fibers. Myosatellite cells can provide additional myonuclei for muscle regeneration or return to a...
1.9K
01:20Myasthenia Gravis: Overview and Treatment
1.2K
Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
1.2K